2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchMeSH KeywordsAutoimmune DiseasesCarcinoma, Non-Small-Cell LungFemaleHumansImmunotherapyKidney NeoplasmsLung NeoplasmsMaleRetrospective StudiesConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2019
Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer
Giri S, Huntington SF. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer. JAMA Oncology 2019, 5: 1066-1066. PMID: 31095252, DOI: 10.1001/jamaoncol.2019.1088.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungChemoradiotherapyConsolidation ChemotherapyCost-Benefit AnalysisHumansLung Neoplasms